Peer-influenced content. Sources you trust. No registration required. This is HCN.

FDA Approves Nivolumab-Ipilimumab Combo for Malignant Pleural Mesothelioma

The US Food and Drug Administration (FDA) approval – the first for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma – was based on a randomized, open-label trial, of 605 patients. The endpoint was to determine if the nivolumab-ipilimumab combo improved overall survival compared to chemotherapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form